How to Get Crestor (Rosuvastatin) in Missouri

Who Can Prescribe Rosuvastatin in Missouri

Any prescriber with an active, unrestricted Missouri license and DEA registration can write a rosuvastatin prescription. That includes physicians (MD and DO), nurse practitioners, and physician assistants.

Missouri revised statute 334.104 grants NPs with a collaborative practice agreement full prescriptive authority for non-controlled substances, and rosuvastatin is not a controlled substance. PAs prescribe under their supervising physician's license per statute 334.735. In practice, this means patients do not need to see a cardiologist or even an internist. A family medicine NP at a walk-in clinic or a telehealth PA can evaluate your cardiovascular risk, order labs, and send a rosuvastatin prescription to your pharmacy the same day.

The 2018 AHA/ACC cholesterol guideline recommends starting moderate-to-high intensity statin therapy for adults with clinical ASCVD, LDL-C of 190 mg/dL or higher, or a 10-year ASCVD risk of 7.5% or greater. Most Missouri prescribers follow this framework when deciding whether rosuvastatin is appropriate. For patients aged 40 to 75 with diabetes and LDL-C between 70 and 189 mg/dL, moderate-intensity statin therapy (rosuvastatin 5 to 10 mg) is recommended without needing a risk calculator [1].

Missouri Telehealth Prescribing Rules

Missouri allows telehealth prescriptions for rosuvastatin. There is no requirement for an initial in-person visit.

Since 2020, Missouri has maintained expanded telehealth statutes (SB 579 and subsequent extensions) that authorize real-time audio-video visits for establishing a patient-prescriber relationship. A prescriber licensed in Missouri can evaluate your lipid panel results, calculate your ASCVD risk score, and transmit a rosuvastatin prescription to any Missouri pharmacy during a single virtual visit. The visit typically takes 10 to 20 minutes.

HealthRX and similar telehealth platforms operating in Missouri pair patients with licensed prescribers who can order labs through Quest, Labcorp, or local Missouri draw sites. Results upload to the patient chart, the prescriber reviews them asynchronously or during a scheduled video visit, and the prescription is sent electronically. Most patients receive their first fill within 3 to 5 business days of completing labs.

One operational note: Missouri law requires that the prescriber document the telehealth encounter in the medical record with the same detail as an in-person visit. Patients should confirm their telehealth provider stores records in compliance with Missouri's health information privacy standards.

Labs Required Before Starting Rosuvastatin

Prescribers in Missouri follow the same lab protocol as the rest of the country. A fasting lipid panel and hepatic function tests are the minimum.

The FDA-approved rosuvastatin label specifies that liver enzymes (ALT and AST) should be measured before initiating therapy and "as clinically indicated thereafter." A fasting lipid panel provides the baseline LDL-C, HDL-C, triglycerides, and total cholesterol needed to select the correct dose. For most adults, rosuvastatin 10 mg daily is the starting dose for moderate-intensity therapy, while 20 to 40 mg daily qualifies as high-intensity therapy per the ACC/AHA guideline [1].

Additional labs a Missouri prescriber might order based on individual risk:

• HbA1c or fasting glucose. Statins carry a small but real risk of new-onset diabetes. The JUPITER trial (N=17,802) reported a physician-diagnosed diabetes rate of 3.0% in the rosuvastatin group versus 2.4% in the placebo group over a median 1.9 years of follow-up [2]. Knowing a patient's baseline glucose status helps contextualize this risk.
• Creatine kinase (CK). Not routinely required, but useful when a patient reports prior statin myalgia or takes medications that increase statin exposure (e.g., cyclosporine, certain protease inhibitors).
• eGFR. Rosuvastatin dose should not exceed 10 mg daily in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) per the FDA label [3].
• TSH. Hypothyroidism is a secondary cause of dyslipidemia and should be excluded before attributing elevated LDL-C to primary hypercholesterolemia.

Quest Diagnostics operates 38 patient service centers across Missouri, and Labcorp has 29. Most telehealth platforms can order labs at either network.

Missouri Pharmacy Access and 503A Compounding

Generic rosuvastatin is stocked at virtually every retail pharmacy in Missouri. Brand Crestor is available but rarely dispensed because the generic is therapeutically equivalent and far cheaper.

Retail chains including Walgreens, CVS, Walmart, and Hy-Vee Pharmacy carry rosuvastatin in 5 mg, 10 mg, 20 mg, and 40 mg tablets. Cash prices without insurance range from approximately $8 to $20 for a 30-day supply, depending on dose and pharmacy. GoodRx and similar discount platforms frequently bring the price below $10. These prices make rosuvastatin one of the most affordable branded-to-generic statin transitions in the formulary.

Missouri-licensed 503A compounding pharmacies can prepare rosuvastatin formulations for patients who need a non-standard dose, a liquid suspension (useful for patients with dysphagia), or a formulation free of specific inactive ingredients that trigger allergies. Under Missouri Board of Pharmacy regulations (20 CSR 2220), a 503A pharmacy must compound pursuant to a valid, patient-specific prescription. These pharmacies are permitted to ship compounded rosuvastatin directly to Missouri addresses.

For patients who prefer mail-order convenience with a manufactured generic, most PBMs (Express Scripts, CVS Caremark, OptumRx) ship 90-day rosuvastatin supplies to Missouri addresses for a single copay tier, often $0 to $15 on commercial plans.

Missouri Medicaid Coverage: The T2D-Only Limitation

This is the single biggest access barrier for low-income Missourians. Missouri Medicaid (MO HealthNet) covers rosuvastatin only when prescribed for type 2 diabetes, not for primary hyperlipidemia or ASCVD prevention alone.

Missouri expanded Medicaid eligibility in 2021, adding approximately 275,000 adults. But MO HealthNet's preferred drug list (PDL) classifies statins under restrictive therapeutic categories. For a hyperlipidemia-only indication, the PDL steers toward older generics like atorvastatin and simvastatin as preferred agents. Rosuvastatin may require prior authorization (PA) and documentation of therapeutic failure on a preferred alternative before MO HealthNet will approve coverage.

The clinical consequence is real. In the JUPITER trial, rosuvastatin 20 mg reduced LDL-C by 50% from a median baseline of 108 mg/dL and cut the combined endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56 to 95% CI 0.46 to 0.69, P<0.00001) over a median follow-up of 1.9 years [2]. Patients who genuinely need rosuvastatin's potency (those requiring >50% LDL-C reduction, or those with documented myalgia on atorvastatin) deserve access regardless of payer.

Workarounds for Medicaid patients:

• Ask the prescriber to submit a PA with documentation of intolerance or therapeutic failure on atorvastatin.
• Use a manufacturer coupon or GoodRx discount to fill at cash price (often less expensive than the Medicaid copay after PA hassle).
• Verify whether your managed care organization (MCO) within MO HealthNet has different PA criteria. Missouri contracts with several MCOs (Home State Health, UnitedHealthcare Community Plan, Healthy Blue), and formulary specifics vary.

Dr. Seth Martin, a preventive cardiologist at Johns Hopkins, has noted: "When a patient has failed atorvastatin or needs LDL lowering beyond what atorvastatin can deliver, rosuvastatin is the logical next step. Formulary restrictions that delay that switch translate into months of suboptimal LDL control" [4].

Prior Authorization Requirements in Missouri

Prior authorization for rosuvastatin in Missouri depends on the payer. Commercial plans rarely require it for generic rosuvastatin. Medicaid and some Medicare Part D plans do.

For MO HealthNet, the PA process typically requires:

1. Diagnosis code. ICD-10 codes E78.00 (pure hypercholesterolemia, unspecified), E78.01 (familial hypercholesterolemia), or I25.10 (ASCVD) on the PA form.
2. Therapeutic failure documentation. Chart notes showing the patient tried a preferred statin (atorvastatin or simvastatin) for at least 30 to 90 days without reaching their LDL-C goal, or experienced adverse effects such as myalgia, elevated CK, or hepatic transaminase elevation.
3. Current labs. A fasting lipid panel drawn within the last 90 days.
4. Prescriber attestation. A statement that rosuvastatin is medically necessary for this specific patient.

Turnaround time for MO HealthNet PA decisions is typically 24 to 72 hours. Missouri law (376.383 RSMo) requires insurers to respond to non-urgent PAs within two business days. If denied, patients have the right to appeal.

For commercial plans, the more common PA trigger is brand Crestor rather than generic rosuvastatin. If a prescriber writes "Crestor, dispense as written," most PBMs will reject it and require a PA or step-therapy override. Switching the prescription to generic rosuvastatin usually eliminates the PA entirely.

Rosuvastatin Dosing and Clinical Evidence

Rosuvastatin is the most potent statin on a milligram-per-milligram basis. The 5 mg dose reduces LDL-C by roughly 38 to 45%, and the 40 mg dose can achieve 55 to 63% reduction.

The STELLAR trial (N=2,431) compared rosuvastatin head-to-head against atorvastatin, simvastatin, and pravastatin across multiple dose levels. At 6 weeks, rosuvastatin 10 mg lowered LDL-C by 45.8%, compared with 36.8% for atorvastatin 10 mg and 28.3% for simvastatin 10 mg [5]. This potency difference matters for patients who need aggressive LDL reduction but want to avoid high-dose side effects.

In the JUPITER trial, participants had LDL-C below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP of 2.0 mg/L or higher). Rosuvastatin 20 mg reduced hsCRP by 37% and LDL-C by 50%. The trial was stopped early at a median of 1.9 years because the treatment group showed a 44% reduction in the primary endpoint (HR 0.56, P<0.00001) [2]. The number needed to treat (NNT) for 2 years to prevent one primary endpoint event was 95.

The 2018 ACC/AHA guideline incorporated JUPITER's findings and now recognizes hsCRP of 2.0 mg/L or higher as a "risk-enhancing factor" that can tip the decision toward statin initiation in borderline-risk patients (10-year ASCVD risk 5 to 7.5%) [1].

For Missouri patients starting rosuvastatin, prescribers typically recheck a fasting lipid panel 4 to 12 weeks after initiation to confirm adequate LDL-C response. If the patient does not achieve the expected percentage reduction, adherence should be assessed before uptitrating.

Transferring a Prescription to Missouri

Patients relocating to Missouri from another state can transfer an existing rosuvastatin prescription with minimal friction.

Missouri Board of Pharmacy rules allow pharmacists to accept prescription transfers from out-of-state pharmacies, including refills remaining on the original prescription. The receiving Missouri pharmacist contacts the originating pharmacy, verifies the prescription details, and processes the transfer. For rosuvastatin (a non-controlled substance), this is straightforward and typically completed within one business day.

If the original prescription has no refills remaining, the Missouri pharmacist can sometimes dispense an emergency supply under Missouri statute 338.010 while the patient establishes care with a new prescriber. The emergency supply is limited and requires pharmacist documentation, so patients should plan to set up a new prescriber relationship (in person or via telehealth) promptly after relocating.

Patients should also verify that their insurance covers rosuvastatin in Missouri. PBM pharmacy networks sometimes differ by state. A pharmacy that was in-network in Kansas may not be in-network in Missouri under the same plan.

Timeline: From First Visit to First Dose

Most Missouri patients can go from initial contact to first rosuvastatin dose in 5 to 10 business days using a telehealth pathway.

A typical timeline:

• Day 1. Complete intake with a telehealth platform. Order labs.
• Days 2 to 4. Visit a lab draw site (Quest, Labcorp, or local hospital lab). Results return in 1 to 2 business days.
• Days 4 to 6. Prescriber reviews labs and conducts a video or asynchronous visit. Prescription sent electronically to the patient's chosen pharmacy.
• Days 5 to 7. Pharmacy fills the prescription. If using mail-order, add 2 to 3 days for shipping.
• Days 7 to 10. Patient begins rosuvastatin.

For patients with recent labs (within 90 days) from a previous provider, the timeline compresses. A prescriber can review existing results and issue a prescription in as little as 24 to 48 hours.

The ACC recommends the first follow-up lipid panel at 4 to 12 weeks after starting therapy [1]. Patients should schedule this lab draw in advance so they do not lose momentum on monitoring.